Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (VSTM) announced publication of two-year follow-up findings from its Phase 2 RAMP 201 ovarian cancer study.
In the 17-patient long-term analysis, median duration of response was 31.1 months and median progression-free survival was 12.9 months, both unchanged from the 109-patient primary analysis. Among patients with KRAS wild-type disease, median response duration rose to 12 months from 9.2 months. For KRAS-mutated disease, median progression-free survival was 19.6 months, down from 22 months. No new safety signals were observed, and 12% of patients discontinued treatment because of adverse events.
The combination has U.S. accelerated approval for adults with previously treated KRAS-mutated recurrent low-grade serous ovarian cancer. Continued approval may depend on confirmation of clinical benefit in a Phase 3 trial.
Verastem Oncology (VSTM) will present RAMP 201 molecular profiling and tumor biomarker analysis at the IGCS meeting on October 2, 2026.
The late-breaking oral presentation concerns its Phase 2 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer. Previously reported results from the RAMP 201J study in Japanese patients will also receive an oral presentation. An external-control comparison with conventional care is scheduled for poster rounds.
Verastem Oncology (VSTM) will host an investor event and webcast on October 14, 2026, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program.
The presentation will provide the first broader safety and efficacy assessment of VS-7375 across these tumor types and follows a clinical update reported in June 2026. VS-7375 is described as an investigational, potent and selective, oral KRAS G12D dual ON/OFF inhibitor designed to bind both active and inactive KRAS G12D states. Verastem is evaluating VS-7375 in the Phase 1/2 TARGET-D 101 trial and three registration-directed Phase 2 studies: TARGET-D 201 in metastatic pancreatic ductal adenocarcinoma, TARGET-D 202 in advanced non-small cell lung cancer, and TARGET-D 203 in metastatic colorectal cancer.
VS-7375 has FDA Fast Track Designations in KRAS G12D-mutated locally advanced or metastatic PDAC and previously treated unresectable locally advanced or metastatic NSCLC.
Verastem Oncology (VSTM)/b) will participate in multiple September 2026 healthcare investor conferences, including Wells Fargo, Cantor, and H.C. Wainwright events.Management will join the Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, then present at the Cantor Global Healthcare Conference on September 10 and the H.C. Wainwright Annual Global Investment Conference on September 14, both in New York City. Live and archived webcasts of these fireside chats will be available for approximately 90 days on the company’s website under “Events & Presentations.”
Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 total revenue of $40.1 million, up from $2.1 million a year earlier, driven by $25.1 million in AVMAPKI FAKZYNJA CO-PACK net product revenue and a $15.0 million COPIKTRA sales milestone. According to Verastem, cash, cash equivalents and investments were $136.4 million at June 30, 2026, or $201.4 million pro forma for a $50 million Oberland Capital royalty financing closing August 28 and the COPIKTRA milestone, supporting a cash runway into 2H 2027.
VS-7375 advanced with first patients dosed in three registration-directed Phase 2 TARGET-D trials, over 200 patients treated in TARGET-D 101, clearance of a 1200 mg QD dose without dose-limiting toxicities, and FDA Fast Track Designation in KRAS G12D-mutated NSCLC. The company plans updated VS-7375 data in October 2026 and aims to complete Phase 2 enrollment by year-end 2026 and start Phase 3 trials in 1H 2027. Q2 2026 GAAP net loss was $34.7 million (or $0.35 per share) on operating expenses of $72.8 million.
Verastem Oncology (Nasdaq: VSTM) announced dosing of the first patient in TARGET-D 203, a Phase 2, open-label, registration-directed trial of VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D-mutated metastatic colorectal cancer (mCRC).
TARGET-D 203 evaluates VS-7375 at 900 mg once daily as monotherapy and in combination with anti-EGFR therapies cetuximab or panitumumab in previously treated mCRC, and in combination with cetuximab plus chemotherapy in the first-line setting. According to Verastem, VS-7375 has shown preliminary anti-tumor activity and a manageable safety profile in the ongoing Phase 1/2 TARGET-D 101 trial across KRAS G12D-driven tumors. With this milestone, all three registration-directed Phase 2 TARGET-D studies in pancreatic, colorectal, and lung cancers are now enrolling, and VS-7375 has received multiple FDA Fast Track Designations in KRAS G12D-mutated pancreatic and NSCLC indications.
Verastem Oncology (Nasdaq: VSTM) announced it will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 p.m. ET. The live audio webcast and slides will be accessible under “Events & Presentations” in the Investor section of the company’s website, with a replay available after the event.
Verastem Oncology (Nasdaq: VSTM) has dosed the first patient in TARGET-D 202, a global, open-label, Phase 2 registration-directed trial of VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, in previously treated unresectable locally advanced or metastatic KRAS G12D-mutated non-small cell lung cancer (NSCLC).
The study evaluates VS-7375 monotherapy at the recommended Phase 2 dose of 900 mg once daily and includes a cohort for NSCLC patients with asymptomatic untreated brain metastases. TARGET-D 202 is Verastem’s second registration-directed Phase 2 trial for VS-7375, alongside TARGET-D 201 in metastatic pancreatic cancer, with TARGET-D 203 planned in metastatic colorectal cancer. According to Verastem Oncology, earlier Phase 1/2 data (TARGET-D 101) showed encouraging anti-tumor activity and a favorable safety profile across multiple KRAS G12D-driven tumors. VS-7375 has received Fast Track Designation from the FDA in pancreatic cancer (July 2025) and KRAS G12D-mutated NSCLC (June 2026).
Verastem Oncology (Nasdaq: VSTM) granted equity awards under Nasdaq Listing Rule 5635(c)(4) to new employees. The company issued 399,750 restricted stock units (RSUs) to 30 hires and stock options for 91,000 shares to one hire at a $4.10 exercise price.
Most RSUs and all options vest 25% after one year, then quarterly over three years, subject to continued service. An additional 6,000 RSUs for one employee vest in full after one year of service.
Verastem Oncology (Nasdaq: VSTM) reported preliminary Phase 1/2 TARGET-D 101 data for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced KRAS G12D-mutated solid tumors.
According to Verastem, VS-7375 showed anti-tumor activity across pancreatic, colorectal and lung cancers with a favorable, mainly low-grade gastrointestinal safety profile, both as monotherapy and in combinations with cetuximab or gemcitabine/nab-paclitaxel.